• Record December 2025 quarter global sales of US$6.1 million, up 38% PCP and 25% on the September 2025 quarter
• Last Twelve Months (LTM) global sales of ~US$21 million (A$32.2 million), up 24% year on year, ~3x the estimated industry growth rate
• Group cash outflow from operations for the quarter was A$1.0 million, including A$1.2 million investment in working capital due to rapidly growing sales

Nova Eye Medical Limited (ASX: EYE), a medical technology company committed to advanced ophthalmic treatment technologies and devices, has reported record global sales of US$6.1 million for the December 2025 quarter, reflecting continued strong demand in the United States and accelerating momentum in Rest of World markets. This outcome represents a 38% increase on the prior corresponding period and a 25% increase on the September 2025 quarter. Sales growth was underpinned by increasing utilization of the Company's iTrack™ technology, which has now been used in approximately 180,000 surgical procedures worldwide. The United States remained the primary growth driver during the quarter, delivering 35% growth on the prior corresponding quarter and contributing to the sixth consecutive half of sales growth since the launch of iTrack™ Advance. Group revenue for the twelve months ended 31 December 2025 reached approximately US$21.0 million (A$32.2 million), representing 24% growth on the prior twelve-month period, significantly outpacing the estimated industry growth rate of approximately 8%. The group cash outflow from operations for the quarter was A$1.0 million, which included an investment of A$1.2 million in working capital to support the rapidly growing sales. The company continues to manage working capital to support growth, and the cash at bank as of 31 December 2025 is A$2.6 million, with an additional A$2 million in undrawn loan facilities.